Navigation Links
Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Date:10/20/2011

NEW YORK, Oct. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Afinitor (Breast Cancer) – Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657207/Afinitor-Breast-Cancer-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Afinitor (Breast Cancer) – Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Afinitor (Breast Cancer) – Analysis and Forecasts to 2020" provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)

- Analysis and review of Afinitor including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Afinitor including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecast for 2013-2020 for Afinitor in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 5

2.1 Breast Cancer Market 5

2.2 Epidemiology 5

2.3 GlobalData Report Guidance 7

3 Breast Cancer: Market Characterization 8

3.1 Breast Cancer Market 8

3.2 Breast Cancer Market Forecasts and CAGR 8

3.3 Drivers of Breast Cancer Market 9

3.3.1 High Prevalence 9

3.3.2 Breast Cancer: Most Frequent Cancer in Women 9

3.3.3 Increasing Breast Cancer Incidence Rate 10

3.3.4 Decreasing Breast Cancer Mortality Rate 11

3.3.5 High Survival Rates of Breast Cancer 13

4 Staging of Breast Cancer: Introduction 15

4.1 Distribution of Patients by Stages 15

4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 18

6 Treatment Options of Breast Cancer 20

6.1 Stage 0 Breast Cancer: Treatment Options 20

6.2 Early Stage Breast Cancer (Excluding Stage 0) 21

6.3 Metastatic Breast Cancer (MBC) 23

6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 23

6.3.2 Cytotoxic Chemotherapy 25

6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Afinitor 29

7.1 Introduction 29

7.2 Mechanism of Action 29

7.3 Clinical Studies 29

7.3.1 Phase I/II trial to Determine the Safety and Efficacy of everolimus (E) plus trastuzumab (T) in Patients with T-resistant Metastatic Breast Cancer 29

7.3.2 Everolimus in Combination with trastuzumab and paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) 30

7.3.3 Everolimus in Combination with exemestane in the Treatment of Postmenopausal Women with ER Positive Locally Advanced or Metastatic Breast Cancer who are Refractory to letrozole or anastrozole (BOLERO-2) 30

7.3.4 Daily everolimus in Combination with trastuzumab and vinorelbine in HER2 Positive women with Locally Advanced or Metastatic Breast Cancer (BOLERO-3) 30

7.4 Approval Status of Afinitor 30

7.5 Factors Affecting Sales of Afinitor 30

7.5.1 Absence of Competition from Neratinib in Japan 30

7.5.2 Patent Expiry of Aromasin before Launch of Afinitor for Breast Cancer 30

7.5.3 High Cost of Afinitor 31

7.6 Drug Risk Benefit Score 31

7.6.1 Efficacy 31

7.6.2 Safety 31

7.6.3 Compliance 31

7.6.4 Dosing Convenience 32

7.7 Intensity of Competition 32

7.8 Sales Forecasts 32

7.8.1 Target Patient Pool of Afinitor 32

7.8.2 Dosing 33

7.8.3 Market Penetration 33

7.8.4 Annual Cost of Therapy 34

7.8.5 Sales Projections of Afinitor 34

8 Appendix 44

8.1 Market Definitions 44

8.2 Abbreviations 44

8.3 Research Methodology 44

8.3.1 Coverage 44

8.3.2 Secondary Research 45

8.3.3 Forecasting 45

8.3.4 Number of Patients Approved to take the Drug 45

8.3.5 Net Penetration of Drug 46

8.3.6 Net Annual Dosing 47

8.3.7 Annual Cost of Therapy 47

8.3.8 Primary Research 47

8.3.9 Expert Panels 47

8.4 Contact Us 48

8.5 Disclaimer 48

8.6 Sources 48

1.1 List of Tables

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5

Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8

Table 3: Five-Year Relative Survival Rates, By Stages 14

Table 4: Approval Status of Afinitor 30

Table 5: Drug Risk Benefit Score of Afinitor 31

Table 6: Annual Cost of Therapy of Afinitor 34

Table 7: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020 35

Table 8: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020 36

Table 9: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020 37

Table 10: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020 38

Table 11: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020 39

Table 12: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020 40

Table 13: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020 41

Table 14: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013–2020 42

1.2 List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6

Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8

Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9

Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10

Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10

Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11

Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11

Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12

Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12

Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13

Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13

Figure 12: Broad Classification of Breast Cancer, By Type 15

Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15

Figure 14: Classification of Invasive Breast Cancer, By Stages 16

Figure 15: Classification of Invasive Breast Cancer, By Treatment 16

Figure 16: Classification of Metastatic or Advanced Breast Cancer 16

Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17

Figure 18: Classification of Locally Advanced Breast Cancer 17

Figure 19: Metastatic Breast Cancer Classification 17

Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18

Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19

Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19

Figure 23: Treatment Options, DCIS Breast Cancer 20

Figure 24: Treatment Options, LCIS Breast Cancer 21

Figure 25: Treatment Options, Stages I, II and IIIA 21

Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22

Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22

Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23

Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24

Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24

Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26

Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27

Figure 33: Drug Model Diagram of Afinitor in the US, EU and Japan 33

Figure 34: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020 35

Figure 35: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020 36

Figure 36: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020 37

Figure 37: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020 38

Figure 38: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020 39

Figure 39: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020 40

Figure 40: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020 41

Figure 41: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013-2020 42

Figure 42: Afinitor, Breast Cancer, Global, Sales Distribution by Country ($m), 2020 43

Figure 43: Drug Model Diagram 46

Figure 44: Patients Approved to take the Drug 47

To order this report:

Pathology Industry: Afinitor (Breast Cancer) – Analysis and Forecasts to 2020

Pathology Business News

More  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. FDA Approves New Indication for Afinitor
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
11. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... a Phase 2 clinical study of sotagliflozin, a dual ... with JDRF, the leading global organization funding type 1 ... 2 clinical trial, which randomized a total of 87 ... 400 mg dose of sotagliflozin compared to a placebo ...
(Date:12/5/2016)... -- Sharn Anesthesia Inc. announced today that it has been ... Salter Labs.  The company also received the 2015 Salter ... sales performance. Salter Labs is a leading ... the market gold standard ECO 2 sampling cannulas. ... Parker Flex-Tip® Endotracheal Tube, which is a leading patient ...
(Date:12/5/2016)... , the first HIPAA compliant software collaboration platform for patients, physicians ... Styku, a California -based software and ... real-time 3D body scanning and analysis. Together with its other strategic ... feel their health like never before. ... , , "Bringing ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... As renowned, ... heard the dangers and downsides of patients who do not do their research and ... of cosmetic dermatology is in the midst of a renaissance and every other month ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released study ... the reproducibility and accuracy of placing precordial electrodes with little cognitive effort and ... last 60 years, studies have shown that single electrode misplacement is one of ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
Breaking Medicine News(10 mins):